Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $13.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target lifted by investment analysts at HC Wainwright from $12.00 to $13.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 192.13% from the company’s current price.

A number of other analysts have also issued reports on CATX. UBS Group lifted their target price on Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. BTIG Research restated a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. B. Riley Financial lifted their price objective on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Royal Bank Of Canada cut their target price on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 17th. Finally, Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average price target of $12.63.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $4.45 on Monday. The firm has a fifty day simple moving average of $4.37 and a 200-day simple moving average of $3.44. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The firm had revenue of $0.04 million for the quarter. Equities analysts expect that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new stake in Perspective Therapeutics during the fourth quarter valued at approximately $84,000. XTX Topco Ltd lifted its holdings in Perspective Therapeutics by 36.5% during the 4th quarter. XTX Topco Ltd now owns 82,476 shares of the company’s stock worth $227,000 after buying an additional 22,074 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $31,000. Opaleye Management Inc. acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $3,257,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $35,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.